Annovis Bio, Inc. (ANVS)
Develops experimental drugs to slow brain degeneration in Alzheimer's and Parkinson's patients
$1.69+0.01%Healthcare
StockGlow Score
Leaning Bearish
BearishBullish
1 year ago-32.7%
The outlook
ANVS is trading near its 52-week low, well below both its 50- and 200-day averages, reflecting a downtrend. Analyst sentiment is bearish overall, though the average price target sits roughly 551% above the current price, suggesting wide disagreement on valuation. The stock remains thinly traded territory with significant volatility risk.
What’s behind the score
Price trendBelow its 50- & 200-day averages
52-week range4% of the way from its 52-week low to high
Price targetAvg target +551% vs current price
Analyst price target
~12-month · 3 analysts$11.00average target+550.9% vs now
Now $1.69
Low $8.00High $17.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$71.9M
52-wk high
$5.50
52-wk low
$1.54
50-day avg
$1.85
200-day avg
$2.51
Trailing P/E
—